Annual Report 2020
Department of Pharmacy
Toshikatsu Kawasaki, Yasuhiko Ichida, Reiko Matsui, Masahito Yonemura, Daisuke Kano, Naoko Kumazawa, Shinya Suzuki, Nobuo Mochizuki, Yuko Ishikawa, Kenji Kawasumi, Misaki Takeno, Shinichi Masuda, Takahiro Akita, Ayumi Komuro, Chihiro Nakada, Yoshihiro Iwamoto, Sayaka Nakajima, Nobue Sato, Yoshiyuki Sano, Akiko Abe, Yui Suzuki, Masaki Tanaka, Kanako Mamishin, Takashi Igarashi, Tsuyoshi Uemoto, Hayato Kamata, Wataru Suenaga, Hidetaka Suzuki, Yumiko Seto, Ken Demachi, Kensuke Mayumi, Asumi Kaneko, Kazuki Sugisaki, Yurie Saotome, Junko Tauchi, Manami Harada, Koki Morishita
Introduction
The main objectives of the Department of Pharmacy are: (1) To promote clinical studies to create new evidence-based data; (2) To provide chemotherapy based on the most updated evidence-based data; and (3) To pursue patient-centered pharmaceutical care.
Our residents’ training program started in 2006. In 2020, six residents joined our department. Presently, we have a total of 18 residents. In addition, our department accepted two trainees from other institutions for our oncology pharmacist training programs in 2020. In 2020, we educated three pharmacy students.
The Department of Pharmacy provides various important services: controlling inventory, dispensing medications, and preparing i.v. solutions for chemotherapy, which include the aseptic mixing of antineoplastic agents, collecting and providing drug information, managing therapeutic drug monitoring, checking treatment regimens for each patient’s chemotherapy, and providing pharmaceutical management and counseling.
Our department reviews the drugs taken by patients before and during their hospitalization. For inpatient care, our department assigns pharmacists to provide medication counseling and drug information for healthcare providers and patients, to pursue effective pharmaceutical care. In outpatient care, our department provides a pharmacy outpatient service in which pharmacists check patients for adverse reactions and doses of antineoplastic agents, especially in the case of oral anticancer medications. We then assess the necessity of supportive care medications and suggest them to physicians. The pharmacy outpatient service also reviews the drugs taken by all patients to assess the optimal time for them to stop their anticoagulants before their surgery or stop taking metformin before examinations with iodinated contrast material. Pharmacists are on duty at the Outpatient Chemotherapy Center as dedicated staff members. The pharmacists provide a Chemotherapy Hotline Service, which is a direct line for our outpatients who have any problems concerning their chemotherapy treatment. In the Outpatient Chemotherapy Center, pharmacists are always available to provide drug information for healthcare providers and patients. We also manage investigational drugs.
Research activities
We have presented oral sessions and poster sessions 16 times at national and international academic conferences. 7 scientific papers were accepted for publication.
List of papers published in 2020
Journal
1. Komuro M, Furuya T, Ohashi Y, Watabe D, Nomura H, Komuro A, Tabei A, Sawamura S, Hyakutake H, Kusu H, Kita Y, Terakado H. Contamination of lenalidomide on blister packages after administration and its exposure countermeasures. Curr Probl Cancer, 100727, 2021
2. Kawasumi K, Kujirai A, Matsui R, Kawano Y, Yamaguchi M, Aoyama T. Survey of serious adverse events and safety evaluation of oral anticancer drug treatment in Japan: A retrospective study. Mol Clin Oncol, 14:12, 2021
3. Suzuki S, Horinouchi A, Uozumi S, Matsuyama C, Kamata H, Kaneko A, Yamaguchi M, Okudera H, Tahara M, Kawasaki T. Impact of outpatient pharmacy interventions on management of thyroid patients receiving lenvatinib. SAGE Open Med, 8:2050312120930906, 2020
4. Matsui R, Suzuki K, Takiguchi T, Nishio M, Koike T, Hayashi T, Seto T, Kogure Y, Nogami N, Fujiwara K, Kaneda H, Harada T, Shimizu S, Kimura M, Kenmotsu H, Shimokawa M, Goto K. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study. BMC Pharmacol Toxicol, 21:72, 2020
5. Okunaka M, Kotani D, Demachi K, Kawazoe A, Yoshino T, Kawasaki T, Shitara K. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. BMC Cancer, 20:1111, 2020
6. Nomura H, Tsuji D, Demachi K, Mochizuki N, Matsuzawa H, Yano T, Daiko H, Fujii S, Kojima T, Itoh K, Kawasaki T. ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. Cancer Chemother Pharmacol, 86:315-324, 2020
7. Nomura H, Hatogai K, Maki Y, Mochizuki N, Tanaka M, Saito S, Daiko H, Kojima T, Kawasaki T. Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer. Support Care Cancer, 28:1849-1854, 2020
8. Frazer MB, Bubalo J, Patel H, Siderov J, Cubilla M, De Lemos M, Dhillon H, Harchowal J, Kuchonthara N, Livinalli A, Macedo R, Mwangi W, Nomura H, O'Connor S, Patterson M, Seadi Torriani M, Yim B, Chan A, Foreman E. International Society of Oncology Pharmacy Practitioners global position on the use of biosimilars in cancer treatment and supportive care. J Oncol Pharm Pract, 26:3-10, 2020
9. Muraishi H, Enomoto R, Katagiri H, Kagaya M, Watanabe T, Narita N, Kano D, Ishikawa S, Ishiyama H. Shift-invariant gamma-ray imaging by adding a detector rotation function to a high-sensitivity omnidirectional Compton camera. Japanese Journal of Applied Physics, 59:90911, 2020
10. Yoshizawa K, Tabuchi M, Ukai S, Suzuki H, Kawano Y, Takasawa R. The Putative Glyoxalase 1 Inhibitor Piceatannol Exhibits Both Anxiolytic-like and Antitumor Effects in Mice. Anticancer Res, 40:3271-3276, 2020
11. Matsuo K, Nomura H, Uchiyama M, Miyazaki M, Imakyure O. Estimating the effect of optimizing anticancer drug vials on medical costs in Japan based on the data from a cancer hospital. BMC Health Serv Res, 20:1017, 2020